Phase I Study of Proteolysis-Targeting Chimera Degrader ARV-110 in Metastatic Castration-Resistant Prostate Cancer

May 29-31, 2020; Online at meetings.asco.org/am
ARV-110, a proteolysis-targeting chimera, shows promising clinical activity in heavily pretreated mCRPC patients who have received at least 1 second-generation AR therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

An expert nurse practitioner provides guidance on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 4, 2022 Expired: October 3, 2023

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN
Program Director
person default Brenda Martone, MSN, ANP-BC, AOCNP
Program Director
Released: September 22, 2022

Downloadable guide for oncology nurses on optimal care of patients with metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN person default Brenda Martone, MSN, ANP-BC, AOCNP Released: September 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings